MEDIFAST, INC. (NYSE:MED) Files An 8-K Regulation FD Disclosure
On June 14, 2017, Medifast, Inc. issued a press release
announcing the Companys adoption of a Rule 10b5-1 repurchase plan
to facilitate its continued share repurchases under its
previously authorized stock repurchase program. The full text of
the press release is attached as Exhibit 99.1.
The information presented in Item 7.01 of this Current Report on
Form 8-K, and Exhibit 99.1, shall not be deemed to be filed for
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act), or otherwise subject to the
liabilities of that section, unless the Company specifically
states that the information is to be considered filed under the
Exchange Act or specifically incorporates it by reference into a
filing under the Securities Act of 1933, as amended, or the
|Item 9.01.||Financial Statements and Exhibits.|
Press release dated June 14, 2017 titled Medifast Announces
10b5-1 Plan to Facilitate Continued Share Repurchases.
About MEDIFAST, INC. (NYSE:MED)
Medifast, Inc. (Medifast) is engaged in the production, distribution and sale of weight loss, weight management and healthy living products, and other consumable health and diet products. The Company operates through its subsidiaries, Jason Pharmaceuticals, Inc., Take Shape For Life, Inc., Jason Enterprises, Inc., Medifast Franchise Systems (MFSI), Inc., Jason Properties, LLC, Medifast Nutrition, Inc. and Seven Crondall, LLC. Its product lines include weight loss, weight management, and healthy living meal replacements, snacks, hydration products and vitamins. It provides weight loss, weight management and healthy living products and programs through multiple channels of distribution: direct to consumer channel through its Website and in-house call centers; Take Shape For Life; Franchise Medifast Weight Control Centers, and a national network of physicians. It offers its products under the Medifast, Thrive by Medifast, Optimal Health by Take Shape For Life and Essential 1 brands.